Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: BPTF

Gene summary for BPTF

Gene summary.

Gene information	Species	Human
	Gene symbol	BPTF
	Gene ID	2186
	Gene name	bromodomain PHD finger transcription factor
	Gene Alias	FAC1
	Cytomap	17q24.2
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	Q12830

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2186	BPTF	C30	Human	Oral cavity	OSCC	1.71e-21	1.32e+00	0.3055
2186	BPTF	C38	Human	Oral cavity	OSCC	3.35e-06	1.18e+00	0.172
2186	BPTF	C43	Human	Oral cavity	OSCC	3.86e-07	2.18e-01	0.1704
2186	BPTF	C46	Human	Oral cavity	OSCC	2.93e-02	2.86e-01	0.1673
2186	BPTF	C51	Human	Oral cavity	OSCC	2.55e-06	6.40e-01	0.2674
2186	BPTF	C06	Human	Oral cavity	OSCC	1.49e-03	1.10e+00	0.2699
2186	BPTF	C08	Human	Oral cavity	OSCC	3.22e-46	1.09e+00	0.1919
2186	BPTF	C09	Human	Oral cavity	OSCC	3.94e-04	4.68e-01	0.1431
2186	BPTF	LN22	Human	Oral cavity	OSCC	1.05e-06	1.33e+00	0.1733
2186	BPTF	EOLP-1	Human	Oral cavity	EOLP	7.37e-13	4.08e-01	-0.0202
2186	BPTF	NEOLP-2	Human	Oral cavity	NEOLP	2.15e-04	2.83e-01	-0.0196
2186	BPTF	NEOLP-3	Human	Oral cavity	NEOLP	2.04e-03	2.66e-01	-0.0191
2186	BPTF	SYSMH1	Human	Oral cavity	OSCC	5.22e-24	6.18e-01	0.1127
2186	BPTF	SYSMH2	Human	Oral cavity	OSCC	4.97e-21	7.89e-01	0.2326
2186	BPTF	SYSMH3	Human	Oral cavity	OSCC	3.28e-43	1.05e+00	0.2442
2186	BPTF	SYSMH4	Human	Oral cavity	OSCC	1.28e-04	1.27e-01	0.1226
2186	BPTF	SYSMH5	Human	Oral cavity	OSCC	1.70e-16	6.21e-01	0.0647
2186	BPTF	SYSMH6	Human	Oral cavity	OSCC	1.09e-11	4.54e-01	0.1275
2186	BPTF	HTA12-15-2	Human	Pancreas	PDAC	9.35e-05	6.96e-01	0.2315
2186	BPTF	HTA12-25-1	Human	Pancreas	PDAC	1.81e-10	1.02e+00	0.313

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00018927	Breast	Precancer	embryonic placenta development	14/1080	82/18723	2.30e-04	3.48e-03	14
GO:00486087	Breast	Precancer	reproductive structure development	43/1080	424/18723	2.36e-04	3.56e-03	43
GO:00614587	Breast	Precancer	reproductive system development	43/1080	427/18723	2.75e-04	4.00e-03	43
GO:00018907	Breast	Precancer	placenta development	19/1080	144/18723	6.26e-04	7.78e-03	19
GO:00017017	Breast	Precancer	in utero embryonic development	35/1080	367/18723	2.47e-03	2.27e-02	35
GO:19900908	Breast	Precancer	cellular response to nerve growth factor stimulus	9/1080	53/18723	3.05e-03	2.62e-02	9
GO:19900896	Breast	Precancer	response to nerve growth factor	9/1080	56/18723	4.47e-03	3.47e-02	9
GO:004860812	Breast	IDC	reproductive structure development	60/1434	424/18723	2.71e-06	1.03e-04	60
GO:006145813	Breast	IDC	reproductive system development	60/1434	427/18723	3.41e-06	1.24e-04	60
GO:000189013	Breast	IDC	placenta development	25/1434	144/18723	9.19e-05	1.78e-03	25
GO:000189213	Breast	IDC	embryonic placenta development	16/1434	82/18723	4.28e-04	5.84e-03	16
GO:199008912	Breast	IDC	response to nerve growth factor	11/1434	56/18723	3.08e-03	2.61e-02	11
GO:000170113	Breast	IDC	in utero embryonic development	42/1434	367/18723	5.85e-03	4.24e-02	42
GO:004860821	Breast	DCIS	reproductive structure development	57/1390	424/18723	9.06e-06	2.45e-04	57
GO:006145822	Breast	DCIS	reproductive system development	57/1390	427/18723	1.12e-05	2.92e-04	57
GO:000189022	Breast	DCIS	placenta development	25/1390	144/18723	5.57e-05	1.13e-03	25
GO:000189221	Breast	DCIS	embryonic placenta development	16/1390	82/18723	3.02e-04	4.38e-03	16
GO:199008922	Breast	DCIS	response to nerve growth factor	11/1390	56/18723	2.42e-03	2.18e-02	11
GO:000170122	Breast	DCIS	in utero embryonic development	41/1390	367/18723	5.74e-03	4.13e-02	41
GO:00018908	Cervix	CC	placenta development	40/2311	144/18723	4.59e-07	1.77e-05	40

Page: 1 2 3 4 5 6 7 8 9 10 11

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

TF	Cell Type	Tissue	Disease Stage	Target Gene	RSS	Regulon Activity
BPTF	CD8TEFF	Breast	IDC	PLCG2,DDX17,SYNE2, etc.	7.55e-02
BPTF	ASC	Colorectum	SER	ARL17B,HNF1A-AS1,MT-ATP8, etc.	1.20e-01
BPTF	CD8TEXINT	Stomach	CAG	GRAMD2B,MCTP2,PACS1, etc.	1.82e-02
BPTF	CD4TN	Stomach	CAG	GRAMD2B,MCTP2,PACS1, etc.	1.17e-02
BPTF	CD4TN	Stomach	CSG	GRAMD2B,MCTP2,PACS1, etc.	8.54e-02
BPTF	MAIT	Stomach	SIM	GRAMD2B,MCTP2,PACS1, etc.	4.20e-02
BPTF	LYMEND	Stomach	ADJ	PHF14,PLA2G2A,MT-ND2, etc.	1.50e-02
BPTF	MVA	Stomach	CAG	PHF14,PLA2G2A,MT-ND2, etc.	6.16e-02
BPTF	CAF	Stomach	CSG	PHF14,PLA2G2A,MT-ND2, etc.	1.16e-01
BPTF	MVA	Stomach	Healthy	PHF14,PLA2G2A,MT-ND2, etc.	3.92e-02

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1 2

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

BPTF

SNV

Missense_Mutation

novel

c.4221N>G

p.Ile1407Met

p.I1407M

Q12830

protein_coding

tolerated_low_confidence(0.28)

benign(0.295)

TCGA-A7-A4SE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

BPTF

SNV

Missense_Mutation

novel

c.587N>A

p.Ser196Asn

p.S196N

Q12830

protein_coding

deleterious(0)

probably_damaging(0.943)

TCGA-A8-A07W-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

exemestane

BPTF

SNV

Missense_Mutation

c.6194N>C

p.Arg2065Thr

p.R2065T

Q12830

protein_coding

deleterious(0)

probably_damaging(0.919)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

BPTF

SNV

Missense_Mutation

c.5514N>G

p.Ile1838Met

p.I1838M

Q12830

protein_coding

deleterious(0.01)

possibly_damaging(0.847)

TCGA-BH-A0DZ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

docetaxel

BPTF

SNV

Missense_Mutation

c.6368N>T

p.Ser2123Leu

p.S2123L

Q12830

protein_coding

deleterious(0.02)

benign(0.164)

TCGA-BH-A2L8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

BPTF

SNV

Missense_Mutation

c.5401C>A

p.Pro1801Thr

p.P1801T

Q12830

protein_coding

deleterious(0.01)

possibly_damaging(0.908)

TCGA-C8-A132-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

BPTF

SNV

Missense_Mutation

c.2908N>C

p.Asp970His

p.D970H

Q12830

protein_coding

tolerated(0.07)

possibly_damaging(0.548)

TCGA-C8-A26Y-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

BPTF

SNV

Missense_Mutation

c.4442N>G

p.Ser1481Cys

p.S1481C

Q12830

protein_coding

tolerated_low_confidence(0.14)

possibly_damaging(0.634)

TCGA-D8-A1JA-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

BPTF

SNV

Missense_Mutation

c.2053N>C

p.Glu685Gln

p.E685Q

Q12830

protein_coding

deleterious(0.02)

benign(0.076)

TCGA-D8-A1JC-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

BPTF

SNV

Missense_Mutation

c.751G>A

p.Glu251Lys

p.E251K

Q12830

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
2186	BPTF	TRANSCRIPTION FACTOR	inhibitor	252827533

Page: 1